發(fā)布時間：2018-08-09 08:49

【摘要】：目的分析新型雌激素受體GPR30表達對子宮內(nèi)膜癌患者預(yù)后的影響并探討其與雌、孕激素表達的關(guān)系。方法收集該院婦產(chǎn)科經(jīng)病理確診為子宮內(nèi)膜癌的石蠟切片,采用免疫組化法檢測GPR30、雌激素受體、孕激素受體表達,并分析其對子宮內(nèi)膜癌的臨床意義和分析三者間的關(guān)系。結(jié)果 GPR30陽性表達率與子宮內(nèi)膜癌的FIGO分期、組織分級以及肌層浸潤深度有關(guān)聯(lián)(P0.05),與淋巴結(jié)轉(zhuǎn)移無明顯相關(guān)性(P0.05)。GPR30表達陽性率在子宮內(nèi)膜癌中表達顯著高于增殖期子宮內(nèi)膜(P0.05),PR表達陽性率在子宮內(nèi)膜癌與增殖期子宮內(nèi)膜差異顯著(P0.05),ER表達陽性率在兩者間無差異(P0.05)。子宮內(nèi)膜癌GPR30與ER陽性共表達率為61.2%(30/49),呈正相關(guān)(r=0.315,P=0.021);與PR陽性共表達率為57.1%(28/49),呈正相關(guān)(r=0.303,P=0.027)。結(jié)論 GPR30陽性表達對子宮內(nèi)膜癌的病理分期、組織分級以及肌層浸潤深度相關(guān),對子宮內(nèi)膜癌預(yù)后產(chǎn)生重要作用;GPR30與ER、PR間存在共表達的交談或調(diào)節(jié)作用。
[Abstract]:Objective to investigate the effect of novel estrogen receptor (GPR30) expression on the prognosis of endometrial carcinoma and its relationship with estrogen and progesterone expression. Methods paraffin sections of endometrial carcinoma diagnosed by pathology in gynecology and obstetrics department were collected, and the expression of GPR30, estrogen receptor and progesterone receptor were detected by immunohistochemical method. The clinical significance of GPR30, estrogen receptor and progesterone receptor in endometrial carcinoma were analyzed. Results the positive expression rate of GPR30 was correlated with the FIGO stage of endometrial carcinoma. Tissue grade and depth of myometrial invasion were correlated (P0.05), but there was no significant correlation between GPR30 expression and lymph node metastasis (P0.05). The positive rate of GPR30 expression in endometrial carcinoma was significantly higher than that in proliferative endometrial carcinoma (P0.05). The positive rate of PR expression in endometrial carcinoma and proliferative phase was significantly higher than that in proliferative endometrial carcinoma (P0.05). There was no significant difference in ER expression between endometrium and endometrium (P0.05). The coexpression rate of GPR30 and ER in endometrial carcinoma was 61.2% (30 / 49), which was positively correlated with PR (57.1%, 28 / 49) and with PR (0.303%, 0.027). Conclusion the positive expression of GPR30 is related to the pathological stage, histological grade and depth of myometrial invasion in endometrial carcinoma, and plays an important role in the prognosis of endometrial carcinoma.
【作者單位】： 武漢科技大學(xué)附屬漢陽醫(yī)院婦產(chǎn)科;
【分類號】：R737.33

【相似文獻】

相關(guān)期刊論文 前4條

1 王植紅;;新型雌激素受體GPR30在子宮內(nèi)膜癌中的表達及其臨床意義[J];中國醫(yī)學(xué)創(chuàng)新;2012年20期

2 鄭麗華;程忠平;;雌激素跨膜受體GPR30及其在子宮內(nèi)膜癌和卵巢癌中的研究進展[J];國際婦產(chǎn)科學(xué)雜志;2014年04期

3 田瑞娟;王利鳳;王增勇;許麗娟;王悅冰;李洋;石巖蓉;朱穎軍;林婉君;李董;;新型雌激素受體GPR30抑制子宮肌瘤平滑肌細胞的增殖[J];南開大學(xué)學(xué)報(自然科學(xué)版);2014年03期

4 ;[J];;年期

相關(guān)博士學(xué)位論文 前1條

1 田瑞娟;雌激素受體GPR30在人子宮肌瘤以及血管平滑肌細胞中的作用和機理研究[D];南開大學(xué);2013年

相關(guān)碩士學(xué)位論文 前1條

1 王沖;新型雌激素受體GPR30在子宮內(nèi)膜癌中的表達及其臨床意義的研究[D];河北醫(yī)科大學(xué);2009年

，

本文編號：2173558